Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-label, Clinical Trial of Intratumoural Ixovex-1 as Single Agent Therapy or in Combination With Pembrolizumab in Palpable Solid Tumours

NCT06549946 is registered in ClinicalTrials.gov with Psivac Ltd as lead sponsor.

NCT NCT06549946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06549946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-label, Clinical Trial of Intratumoural Ixovex-1 as Single Agent Therapy or in Combination With Pembrolizumab in Palpable Solid Tumours
Lead sponsor
Psivac Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 17, 2024
Completion date
January 30, 2027
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, solid tumor